EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)

被引：0
|
作者：
Gratacos-Masmitja, J. [1 ]
Turkiewicz, A. [2 ]
Dokoupilova, E. [3 ,4 ]
Gellett, A. M. [5 ]
Sprabery, T. [5 ]
Geneus, V. J. [5 ]
Constantin, A. [6 ]
机构：
[1] Univ Hosp Parc Tauli Sabadell, Barcelona, Spain
[2] Rheumatol Associates PC, Birmingham, AL USA
[3] Med Plus Sro, Uherske Hradiste, Czech Republic
[4] Univ Vet & Pharmaceut Sci, Dept Pharmaceut, Fac Pharm, Brno, Czech Republic
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Hosp Pierre Paul Riquet, Toulouse, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1482
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0411
引用
收藏
页码：1154 / 1154
页数：1
相关论文
共 50 条
  • [31] Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
    Nash, Peter
    Kirkham, Bruce
    Okada, Masato
    Rahman, Proton
    Combe, Benard
    Burmester, Gerd-Ruediger
    Adams, David H.
    Kerr, Lisa
    Lee, Chin
    Shuler, Catherine L.
    Genovese, Mark
    LANCET, 2017, 389 (10086): : 2317 - 2327
  • [32] EFFICACY OF IXEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AXIAL PAIN STARTING BEFORE AGE 45: A SUBGROUP ANALYSIS OF SPIRIT-P1 AND SPIRIT-P2 PHASE 3 CLINICAL TRIALS
    Deodhar, Atul
    Ogdie, Alexis
    Muram, Talia
    Sandoval, David
    Geneus, Vladimir
    Nash, Peter
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1838 - 1838
  • [33] Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors
    Kirkham, Bruce
    Sesin, Carlos
    Gellett, Amanda M.
    Sprabery, Aubrey T.
    Lin, Chen-Yen
    Turkiewicz, Anthony
    RHEUMATOLOGY, 2021, 60 (09) : 4367 - 4372
  • [34] IXEKIZUMAB MAKES VERY LOW DISEASE ACTIVITY AND REMISSION WITH PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS FOR UP TO 1 YEAR: SPIRIT-P1 AND SPIRIT-P2 TRIALS
    Coates, L. C.
    Husni, M. E.
    Lespessailles, E.
    Kerr, L.
    Gallo, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 375 - 375
  • [35] Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results (Jun, 10.1007/s10067-022-06218-8, 2022)
    Coates, Laura C.
    Mease, Philip
    Kronbergs, Andris
    Helt, Cameron
    Sandoval, David
    Park, So Young
    Combe, Bernard
    Nash, Peter
    Deodhar, Atul
    CLINICAL RHEUMATOLOGY, 2022, 41 (10) : 3261 - 3261
  • [36] Efficacy of Ixekizumab in Different Phenotypes of Patients with Active Psoriatic Arthritis (PsA): Results from the Spirit Trials
    Behrens, Frank
    Nash, Peter
    Gossec, Laure
    Leage, Soyi Liu
    de la Torre, Inmaculada
    Sapin, Christophe
    Kurzawa, Monika
    Burmester, Gerd R.
    Smolen, Josef S.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [37] Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
    Mease, Philip J.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Gossec, Laure
    Mcinnes, Iain B.
    Ritchlin, Christopher T.
    Landewe, Robert B. M.
    Asahina, Akihiko
    Ink, Barbara
    Heinrichs, Andrea
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1363 - 1382
  • [38] IXEKIZUMAB IMPROVES NAIL AND SKIN PSORIASIS THROUGH 52 WEEKS OF TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO RANDOMIZED, DOUBLE-BLIND, PHASE 3, CLINICAL TRIALS (SPIRIT-P1 AND SPIRIT-P2)
    Merola, Joseph F.
    Kishimoto, Mitsumasha
    Adams, David
    Park, So Young
    Thaci, Diamant
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 16 - 16
  • [39] Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1) (vol 45, pg 367, 2018)
    Van der Heijde, D.
    Gladman, D. D.
    Kishimoto, M.
    Okada, M.
    Rathmann, S. S.
    Moriarty, S. R.
    Shuler, C. L.
    Carlier, H.
    Benichou, O.
    Mease, P. J.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (11) : 1608 - 1608
  • [40] Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
    Combe, Bernard
    Emery, Paul
    Boonen, Annelies
    Leage, Soyi Liu
    Sapin, Christophe
    Bello, Natalia
    Dougados, Maxime
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345